Top

Cancer Chemotherapy and Pharmacology

Published in:

01-06-2007 | Original Article

Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells

Authors: Ram Varma, Suzanne Hector, William R. Greco, Kimberly Clark, Lesleyann Hawthorn, Carl Porter, Lakshmi Pendyala

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2007

Abstract

Purpose

As a follow-up to our previous findings that platinum drugs induce a key enzyme in polyamine catabolism, gene expression profiling and mathematical modeling were used to define the effects of cisplatin and oxaliplatin on the expression of polyamine metabolic pathway genes in A2780 human ovarian carcinoma cells.

Methods

Time-course and concentration–effect experiments were each carried out with cisplatin or oxaliplatin in two separate experiments and cells subjected to gene expression profiling using Affymetrix array technology. Time-course data were modeled using exponential increase and decrease models. Concentration–effect data were modeled using a four parameter Hill model.

Results

Gene expression profiling of human ovarian carcinoma A2780 cells after exposure to either cisplatin or oxaliplatin indicates that the expression of several genes involved in polyamine pathway is affected by the platinum drugs. Mathematical/Statistical modeling of the data from time-course and concentration–effect experiments of gene expression from nine polyamine pathway genes represented on the HGU95Av2 chip, indicates that three biosynthetic pathway genes (SAMDC, ODC1 and SRM) are down-regulated and one catabolic pathway gene (SSAT) is up-regulated. Expression changes were similar for different probesets for a given gene on the array. Studies on the induction of SSAT by platinum drugs suggested by the Affymetrix data have been previously validated from this laboratory (Hector et al. in Mol Cancer Ther 3:813–822, 2004). Here, the effects of oxaliplatin exposure on SAMDC and ODC observed by Affymetix are validated with real time QRT-PCR.

Conclusion

The data indicate a concerted effect of platinum drugs on the polyamine metabolic pathway with down-regulation in the expression of several enzyme genes involved in biosynthesis and many-fold up-regulation in expression of SSAT, an acetylating enzyme gene that is critically involved in polyamine catabolism and export.

Abeloff MD, Rosen ST, Luk GD, Baylin SB, Zeltzman M, Sjoerdsma A (1986) Phase II trials of α-difluoromethylornithine, an inhibitor of polyamine synthesis in advanced small cell lung cancer and colon cancer. Cancer Treat Rep 70:843PubMed

Almon RR, Dubois DC, Jin JY, Jusko WJ (2005) Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series. AAPS J 7:E156–E194PubMedCrossRef

Almon RR, Lai W, Dubois DC, Jusko WJ (2005) Corticosteroid-regulated genes in rat kidney: mining time series array data. Am J Physiol Endocrinol Metab 289:E870–E882PubMedCrossRef

Boulikas T, Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 10:1663–1682PubMed

Canizares F, Salinas J, de las Heras M, Diaz J, Tovar I, Martinez P, Penafiel R (1999) Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Clinical Cancer Research 5:2035–2041PubMed

Canizares F, Salinas J, de las Heras M, Diaz J, Tovar I, Martinez P, Penafiel R (1999) Prgnostic value of ornithine decarboxylase and polyamines in human breast cancer: correlations with clinicopathological parameters. Clin Cancer Res 5:2035–2041PubMed

Casero RAJ, Celano P, Ervin SJ, Porter CW, Bergeron RJ, Libby PR (1989) Differential induction of spermidine/spermine N¹-acetyltransferase in human lung cancer cells by the bis(ethyl)polyamine analogues. Can Res 49:3829–3833

Chen Y, Kramer D, Jell J, Vujcic S, Porter CW (2003) siRNA suppression of polyamine analogue-induced spermidine/spermine N¹-acetyltransferase. Mol Pharm 64:1153–1159CrossRef

Chen Y, Kramer DL, Li F, Porter CW (2003) Loss of inhibitor of apoptosis proteins as a determinant of polyamine-analogue-induced apoptosis in human melanoma cells. Oncogene 22:4964–4972PubMedCrossRef

10.

Devereux W, Wang Y, Stewart TM, Hacker A, Smith R, Frydman B, Valasinas AL, Reddy VK, Marton LJ, Ward TD, Woster PM, Casero RA (2003) Induction of the PAOh1/SMO polyamine oxidase by polyamine analogues in human lung carcinoma cells. Cancer Chemother Pharmacol 52:383–390PubMedCrossRef

11.

Di Francesco AM, Riccardi R (2002) Cellular and molecular aspects of the drugs of the future. Cell Mol Life Sci 59:1914–1927PubMedCrossRef

12.

Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863–14868PubMedCrossRef

13.

Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48:398–406PubMedCrossRef

14.

Hector S, Hawthorn L, Greco W, Pendyala L (2002) Gene expression profiles after oxaliplatin treatment in A2780 ovarian carcinoma cells. Proc AACR 43:62

15.

Hector S, Porter CW, Kramer DL, Clark K, Prey J, Kiesel N, Diegelman P, Chen Y, Pendyala L (2004) Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N ¹, N ¹¹-diethylnorspermine at the level of spermidine/spermine N ¹-acetylransferase. Mol Cancer Ther 3:813–822PubMed

16.

Kahana C, Asher G, Shaul Y (2005) Mechanisms of protein degradation. An odyssey with ODC. Cell Cycle 4:1461–1464PubMed

17.

Kramer DL, Vujcic S, Diegelman P, Alderfer J, Miller JT, Black JD, Bergeron RJ, Porter CW (1999) Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. Can Res 59:1278–1286

18.

Levasseur LM, Slocum HK, Rustum YM, Greco WR (1998) Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res 58:5749–5761PubMed

19.

Libby PR, Henderson M, Bergeron RJ, Porter CW (1989) Major increases in spermidine/spermine-N1-acetyltransferase activity by spermine analogues and their relationship to polyamine depletion and growth inhibition in L1210 cells. Cancer Res 49:6226–6231PubMed

20.

Mangold U (2005) The antizyme family: polyamines and beyond. IUBMB Life 57:671–676PubMedCrossRef

21.

Mohan RR, Challa A, Gupta S, Bostwick DG, Ahmad N, Agarwal R, Marengo SR, Amini SB, Paras F, MacLennan GT, Resnick MI, Mukhtar H (1999) Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 5:143–147PubMed

22.

Porter C, Herrera-Omelas L, Pera P, Petrelli NF, Mittleman A (1987) Polyamine biosynthetic activity in normal and neoplastic human colorectal tissues. Cancer 60:1275–1281PubMedCrossRef

23.

Porter CW, Bernacki RJ, Miller J, Bergeron RJ (1993) Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action. Can Res 53:581–586

24.

Porter CW, Ganis B, Libby PR, Bergeron RJ (1991) Correlations between polyamine analogue-induced increases in spermidine/spermine N¹-acetyltransferase activity, polyamine pool depletion, and growth inhibition in human melanoma cell lines. Cancer Res 51:3715–3720PubMed

25.

Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, et al (1990) Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Nat Cancer Inst 82:1113–1118PubMedCrossRef

26.

Scalabrino G, Ferioli ME (1985) Degree of enhancement of polyamine biosynthetic decarboxylase activities in human tumors: A useful new index of degree of malignancy. Cancer Detect Prev 8:11PubMed

27.

Shappell NW, Miller JT, Bergeron RJ, Porter CW (1992) Differential effects of the spermine analog, N ¹,N ¹²-bis(ethyl)-spermine, on polyamine metabolism and cell growth in human melanoma cell lines and melanocytes. Anticancer Res 12:1083–1089PubMed

28.

Thomas T, Thomas TJ (2001) Polyamines in cell growth and cell death: molecular mechanisms and therapetic applications. Cell Mol Life Sci 58:244–258PubMedCrossRef

29.

Thomas T, Balabhadrapathruni S, Gallo MA, Thomas TJ (2002) Development of polyamine analogs as cancer therapeutic agents. [Review]. Oncol Res 13:123–135PubMed

30.

Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. [erratum appears in Proc Natl Acad Sci USA 2001 98(18):10515]. Proc Natl Acad Sci USA 98:5116–5121

31.

Urdiales JL, Medina MA, Sanchez-Jimenez F (2001) Polyamine metabolism revisited. Eur J Gastroenter 13:1015–1019CrossRef

32.

Varma R, Hector S, Pendyala L, Greco WR (2005) Modeling and analysis of drug concentration-effect and time course patterns in gene expression data from microarray experiments. Proc AACR 46:2

33.

Varma RR, Hector S, Clark K, Greco WR, Hawthorn L, Pendyala L (2005) Gene expression profiling of a clonal isolate of oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Oncol Rep 14:925–932PubMed

34.

Vujcic S, Diegelman P, Bacchi CJ, Kramer DL, Porter CW (2002) Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin. Biochem J 367:665–675PubMedCrossRef

35.

Vujcic S, Halmekyto M, Diegelman P, Gan G, Kramer DL, Janne J, Porter CW (2000) Effects of conditional overexpression of spermidine/spermine N ¹-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem 275:38319–38328PubMedCrossRef

36.

Vujcic S, Liang P, Diegelman P, Kramer DL, Porter CW (2003) Genomic identification and biochemical characterization of the mammalian polyamine oxidase involved in polyamine back-conversion. Biochem J 370:19–28PubMedCrossRef

Title: Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells
Authors: Ram Varma
Suzanne Hector
William R. Greco
Kimberly Clark
Lesleyann Hawthorn
Carl Porter
Lakshmi Pendyala
Publication date: 01-06-2007
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2007
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-006-0325-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2007

Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer

Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma

Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models

Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck

Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks

Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride

Keynote webinar | Spotlight on antibody–drug conjugates in cancer